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1. Introduction 
Epidemiological data suggests that hypertension remains a major modifiable risk factor for 
cardiovascular disease  in Western countries. The prevalence of the disease among adults in 
Slovenia aged 25–64 years is between 40–50% (CINDI, 2006). The early detection and 
severity of typical target organ damage and secondary diseases are key determinants of 
cardiovascular prognosis in patients suffering from arterial hypertension (Mancia et al., 
2009). The classic manifestations of hypertensive target organ damage include: damage in 
the conduit arteries (atherosclerosis), kidney (nephrosclerosis) and heart (left ventricular 
hypertrophy, diastolic dysfunction, reduction of coronary reserve). The recommendations of 
medical societies specializing in hypertension do not base risk stratification solely on blood 
pressure (BP), but rather take into account concomitant cardiovascular diseases as well 
(Mancia et al., 2009). Early detection and adequate management of hypertensive target 
organ damage can slow or prevent damage, or even allow disease regression where organ 
damage is still at reversible stage. Therefore, the diagnosis of hypertensive target organ 
damage is of decisive importance. The purpose of this review is to summarize current and 
emerging approaches to the pathophysiology, early detection and treatment of hypertensive 
disease. 
2. Etiopathogenesis of essential hypertension 
In spite of intensive investigation, etiology of essential hypertension (EH), which accounts 
for 90-95% of all cases of arterial hypertension remains poorly understood. Heredity is a 
predisposing factor (Sagnella & Swift, 2006), but environmental factors (e.g., dietary Na+, 
obesity, sedentary lifestyle, stress, alcohol intake) seem to increase the risk of developing 
hypertension (Kyrou et al., 2006; Lackland & Egan, 2007).  
Pathogenesis is also not known. Because BP equals cardiac output (CO) × total peripheral 
vascular resistance (TPR), pathogenic mechanisms must involve increased CO, increased 
TPR, or both. Many theories have been proposed to explain this equation; the 
microcirculation theory is the most attractive among them. In accordance with this theory 
the primary defect involves small resistance vessels, leading to increased TPR and sustained 
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elevated BP. Several basic studies support this theory as functional and morphological 
abnormalities in the microcirculation may appear very early in evolving EH. Functional 
changes (endothelial dysfunction) could be the first event; later on, morphological changes 
of the vasculature ensue. The latter include increased media/lumen ratio due to 
hypertrophy and/or hyperplasia of myocytes in the vessel wall and decreased density 
(rarefaction) of blood vessels on biopsy (Mark, 1984; Schiffrin, 1992; Sivertsson et al., 1979; 
Takeshita & Allyn, 1980). Plethysmographic studies suggest that TPR is increased even in 
normotensive young men with a familial predisposition to hypertension (Takeshita et al., 
1982). 
Endothelial cells (EC) have a pivotal role in the maintenance of the basal tone and 
modulation of TPR. In the endothelium releases several biologically active substances, 
which maintain the homeostasis between circulating blood and arterial wall via autocrine 
and paracrine mechanisms. Vasoconstricting factors (endothelin-1, thromboxane A2, 
angiotensin II) on one side and vasorelaxing factors (prostacyclin, nitric oxide /NO/) on the 
other are secreted by EC (Lüscher, 1994; Vane et al., 1990) (Figure 1.). In their pioneer work 
Furchgott and Zawadzki 1980 reported that EC stimulated by a neurotransmitter 
(acetylcholine) can evoke vasodilation (Furchgott & Zawadzki, 1980). The mediator of these 
responses is a diffusible substance with a half-life of few seconds, the so-called endothelium 
derived relaxing factor – EDRF, which is chemically identical to NO and is continuously 
secreted upon shear stress forces (produced by blood flow) from EC (Hutchinson & Palmer, 
1987; Ignarro et al., 1987). Basal generation of NO keeps arterial circulation in an actively 
dilated state (Schiffrin, 1992). The intracellular mechanism by which NO causes dilation in 
vascular smooth muscle cells involves formation of cyclic 3’,5’-guanosine monophosphate 
(cGMP) via the enzyme soluble guanylyl cyclase, intracellular Ca++-ion depletion and 
consequently relaxation of myocytes (endothelium-dependent dilation) (Palmer et al., 1987; 
Rubany et al., 1986; Wennmalm, 1994). Indeed, many experimental studies have shown that 
NO could contribute to TPR and to modulation of BP (Persson et al., 1990; Rees et al., 1989; 
Vallance et al., 1989). In addition, NO appears to be an endogenous inhibitor of 
norepinephrine in animal studies and thus a modulator of the sympathetic nerve system, a 
mechanism which could also be involved in the pathogenesis of EH (Cohen & Weisbrod, 
1988; Greenberg et al., 1990).  
3. Target organ damage 
3.1 Vascular abnormalities (endothelial dysfunction) in EH 
Recently, works related to the association between EH and sustained endothelial damage 
has gained popularity among hypertension scientists. It remains unclear however whether 
endothelial changes precede the development of hypertension or whether such changes are 
mainly due to long standing elevated BP.  
The term endothelial dysfunction describes several pathological conditions, including 
altered anticoagulant and anti-inflammatory properties in the endothelium, impaired 
modulation of vascular growth, and deregulation of vascular remodeling, decreased 
production of NO and unbalanced production of other different vasoactive substances 
(endothelin-1, thromboxane A2, and angiotensin II) (Moncada et al., 1991). In the literature  
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Fig. 1. Endothelium derived vasoactive substances. The endothelium is a source of relaxing 
(right) and contracting factors (left). AT1, angiotensin receptor; A II, angiotensin II; ACE, 
angiotensin-converting enzyme; Ach, acetylcholine; ADP, adenosine diphosphate; BK, 
bradykinin; cAMP/cGMP, cyclic adenosine/guanosine monophosphate; 5-HT, 5-
hydroxytryptamine (serotonin); ET-1, endothelin-1; L-arg, L-arginine; NO, nitric oxide; NO2–
/NO3–, nitrite/nitrate; O2–, superoxide radical; PGI2, prostacyclin; TGFβ1, transforming 
growth factor β1; Thr, thrombin; TXA2, thromboxane A2; Circles represent receptors; 
Modified from Lüscher, 1994. 
however, the term specifically refers to an impairment of endothelium-dependent 
vasodilation caused by decreased NO bioavailability in the vessel wall (Poredoš, 2002). 
Endothelial dysfunction has been demonstrated in subjects with different risk factors for 
atherosclerosis including arterial hypertension, and in coronary atherosclerotic disease 
(Egashira et al., 1995; Zeiher et al., 1993). We shall now focus on evidences which indicate 
that endothelial dysfunction is a characteristic finding in patients with EH (Taddei & 
Salvetti, 2002).  
Under basal conditions, whole-body NO bioavailability is diminished in hypertension 
(Moncada et al., 1991). With few exceptions (Cockcroft et al., 1994), hypertensive patients 
have shown to have impaired endothelium-dependent vasodilative response of the 
peripheral resistance arteries (usually measured by forearm blood flow using venous 
occlusion plethysmography) to NO stimulants (acetylcholine) (Panza et al., 1993; Panza et 
al., 1990; Taddei et al., 1993), but not to endothelium-independent vasodilators such as 
nitroprusside (Panza et al., 1993). Using B-mode ultrasound the impairment of dilation 
capability of systemic conduit arteries during reactive hyperemia was demonstrated, as was 
reduced vasodilative response to acetylcholine in coronary vessels of patients with EH 
(Treasure et al., 1993; Zeiher et al., 1993; Žižek et al., 2001a; Žižek & Poredoš 2001b). Authors 
postulate that EH like other risk factors for atherosclerosis (hypercholesterolemia, diabetes 
and smoking) damage and change the function of EC (Drexler et al., 1991; Zeiher et al., 
1991). The evidence for a role of defective NO-mediated vasodilation in the etiopathogenesis 
of arterial hypertension has been further strengthened by its recognition in still 
normotensive children of hypertensive parents (Žižek et al., 2001a, Žižek & Poredoš, 2001b). 
As impaired endothelium-dependent vasodilation precedes and predicts the future 
development of hypertension, one could reasonably speculate that endothelial dysfunction 
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is causally related to EH (Rossi et al., 2004). Moreover, it seems that endothelial dysfunction 
is partly inherited but deteriorates further in evolving hypertension – thus suggesting that 
endothelial dysfunction in established hypertension could be the cause and the consequence 
of hypertensive disease (Calver et al., 1992; Žižek et al., 2001a).  
There are relatively few data, albeit controversial, on mechanisms leading to decreased 
production of NO in EH. The majority of investigators attach weight to inherited or 
acquired decreased activity of a key enzyme, NO synthase (Bogle et al., 1995; Mehta et al., 
1994). Recent reports have shown that reduced NO bioactivity may be linked to increased 
circulating level of the endogenous NO synthase inhibitor, asymmetric dimethyl L-arginine 
(Achan et al., 2003). In sustained EH decreased vasodilation was explained by a deficiency 
of L-arginine, the precursor of NO (Panza et al., 1993), inactivation of NO due to free 
radicals formation (Mechta et al., 1994), impeding diffusion to smooth muscle cells (Van de 
Voorde & Leusen, 1986), blunted response of the smooth muscle to pharmacological and 
physiological stimuli (Robinson et al., 1982), and increased production of vasoconstricting 
factors (endothelin-1, angiotensin II) (Lüscher, 1994). 
In addition to NO, prostacyclin (PGI2) is released by EC in response to shear stress, hypoxia 
and to several substances (acetylcholine, substance P, serotonin) which are also released by 
NO (Figure 1.). PGI2 is synthesized by cyclo-oxygenase from arachidonic acid (Vane et al., 
1990). Prostacyclin increases cyclic 3’,5’-adenosine monophosphate (cAMP) in smooth 
muscle cells and platelets. Its platelet inhibitory effects are probably more important than its 
contribution to endothelium-dependent relaxation (Vane et al., 1990). The synergistic effect 
of both PGI2 and NO enhances the antiplatelet and anticoagulant activity of the EC (Pearson 
& Wheeler-Yones 1997; Yang et al., 1994). 
The family of endothelins consists of three closely related peptides: endothelin-1 (ET-1), 
endothelin-2, and endothelin-3 (Figure 1.). EC produce exclusively endothelin-1, which is 
the strongest vasoconstricting factor (Rossi et al., 1999). The release of the peptide is 
modulated by shear stress, epinephrine, angiotensin II, thrombin, inflammatory cytokines 
(tumor necrosis factor-, interleukin-1, -2) and hypoxia (Moncada et al., 1991). There are 
well known interactions between ET-1 and other vasoactive substances. After inhibition of 
the endothelial L-arginine pathway, thrombin and angiotensin II induced ET-1 production is 
augmented (Moncada et al., 1991). ET-1 can release NO and PGI2 from EC, which as a 
negative feedback mechanism reduces peptide production in endothelium and its 
vasoconstrictor action in smooth muscle (Moncada et al., 1991; Rossi et al., 1999). Infusion of 
an ET-1 receptor antagonist in healthy humans leads to vasodilation, indicating a role of ET-
1 in the maintenance of basal vascular tone (Haynes et al., 1996). In some severe 
hypertensive patients ET-1 gene expression and vascular hypertrophy in small resistance 
arteries were reported (Schiffrin et al., 1997). 
Oxidative stress plays an important role in the development of endothelium injury found in 
EH. It is defined as imbalance between production of reactive oxygen species (ROS) and 
antioxidants that neutralize them (Landmesser & Drexler, 2007; Spieker et al., 2000). 
Formation of ROS, resulting in scavenging of NO and reduced NO bioavailability, has been 
suggested as a hallmark of endothelial dysfunction and a pathogenetic mechanism in several 
cardiovascular diseases, including hypertension (Figure 1.) (Schulz et al., 2011). Indeed, 
increased production of ROS has been observed in human hypertension (Higashi et al., 2002; 
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Redon et al., 2003) as well as evidenced in animal models, such as in angiotensin II 
(Landmesser et al., 2002) or in genetically defined hypertension (Nishiyama et al., 2004). 
Increased production of vascular ROS, especially superoxide anion (O2–) contributes 
significantly to functional and morphological alterations in hypertension (Touyz et al., 2004). 
Exaggerated superoxide production and low NO bioavailability lead to endothelial 
dysfunction and hypertrophy of vascular cells promoting atherosclerosis (Figure 1.). It has 
been reported that the enzyme NAD(P)H oxydase plays a major role as the most important 
source of superoxide anion in vascular cells (Zalba et al., 2001). Experimental observations 
indicated an enhanced superoxide generation as a result of the activation of vascular 
NAD(P)H oxydase in hypertension (Griendling et al., 2000). During pulsatile stretch of the 
arterial wall expression of the enzyme is increased, thus enabling a positive feedback 
mechanism between oxidative stress and hypertension (Hishikawa et al., 1997). Although 
NAD(P)H oxydase responds to stimuli such as vasoactive factors, growth factors, and 
cytokines, some recent data suggest a genetic background modulating its expression 
(Landmesser & Drexler, 2007). Oxidative excess is also linked to a pro-inflammatory state of 
the vessel wall. Adhesion and chemotactic molecules upregulated by ROS seem to play a 
key pathophysiological role in the process of atherogenesis (Touyz, 2004). In particular, 
increased O2– production is associated with NO bioinactivation, which influences afferent 
arteriolar tone, tubuloglomerular feedback responses, and sodium reabsorption – all of 
which is paramount in long-term BP regulation (Wilcox, 2002). Moreover, ROS are known to 
quench NO with formation of peroxynitrite, which is a cytotoxic oxidant. Peroxynitrite leads 
to degradation of NO synthase cofactor of tetrahydrobiopterin leading to uncoupling of 
endothelium NO synthase in hypertension and secretion of ROS rather than NO 
(Landmesser et al., 2003). 
The best known regulator of BP and determinant of target organ damage in hypertension is 
the renin-angiotensin-aldosterone system (RAAS). The basic scheme of function has been 
known for a long time; however, recent evidence shows that apart from circulating RAAS, 
tissue RAAS also exists and may well be of greater importance (Hsueh & Wyne, 2011). 
Tissue RAAS is most important in the vessel wall, the heart and the kidney. Constituents of 
RAAS could enter the endothelium or could originate from it (Hsueh & Wyne, 2011). The 
role of angiotensin II in neurohumoral modulation is very well investigated. Angiotensin II 
modifies the vascular tone either directly by activation angiotensin 1 (AT1) receptors in 
vessel wall myocytes or indirectly by stimulation of norepinephrine secretion from the nerve 
endings (Kim & Iwao, 2000; Williams, 2001). Although acute hemodynamic effects of 
angiotensin II are useful, its chronic elevation could have deleterious non-hemodynamic 
consequences. Angiotensin II can cause endothelial dysfunction, vascular stiffness and 
accelerated atherogenesis independently from BP (Williams, 2001). It is proposed that in the 
condition of low plasma renin level for its non-hemodynamic effects an increased 
expression of AT1 receptors could play a role (Figure 1.). Namely, in hypertension 
expression is increased due to pulsatile stretch of arterial wall leading to increased local 
effects of AT1 receptors. This inaugurates increased angiotensin II effects and other 
constituents of RAAS, especially aldosterone (Kim & Iwao, 2000; McMahon, 2001). Harmful 
effects of the latter extend from endothelial dysfunction, fibrosis and inflammation of 
arterial wall to systemic electrolytes and hemodynamic imbalance (Brasier et al., 2002; 
Duprez, 2006). In particular, convincing evidence exist that overactivation of RAAS, or at 
least part of it, may induce ET-1 production and increase angiotensin-converting enzyme 
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(ACE) activity, which splits bradykinin, an important endothelium-derived relaxing factor 
(Watanabe et al., 2005). Angiotensin II has been shown to increase secretion of vascular 
NAD(P)H oxydase and formation of ROS (Hitomi et al., 2007). Indeed, increased production 
of ROS has been observed in human hypertension (Higashi et al., 2002; Redon et al., 2003). 
Endothelial dysfunction is the earliest measurable disturbance in arterial wall function, 
which could be measured in vivo. Early detection of endothelial dysfunction in EH can be 
achieved by the abovementioned methods – namely, measurement of hemodynamic 
changes by ultrasound, measurement of hemodynamic changes by occlusive 
plethysmography, and measurement of circulating markers of defective EC function (ET-1, 
adhesion molecules, tumor necrosis factor–TNF-, von Willebrand’s factor, plasminogen 
activator inhibitor-1, asymmetric dimethyl L-arginine) (Achan et al., 2003; Devaraj et al., 
2003; Treasure et al., 1993; Yang et al., 2010; Žižek et al., 2001a). Detailed description of these 
methods exceeds the purpose of this paper. 
Endothelial dysfunction could be improved or even restored with preventive measures. 
Different studies showed that elimination or management of risk factors (for example 
treating hypercholesterolemia with statins) results in improvement of endothelial 
dysfunction (Wassmann et al., 2001). Considerably less interventional data, albeit 
controversial, are available concerning treatment of EH and endothelial dysfunction of the 
large conduit arteries. Studies on animal models and in humans have shown that 
normalization of BP can restore impaired endothelium-dependent vascular responses 
(Iwatsubo et al., 1997; Lüscher & Vanhoutte, 1987). Conversely, another group of 
investigators failed to show normalization of endothelial dysfunction in conduit arteries 
treated with the same drug (ACE inhibitor) (Eržen et al., 2006). Thus, several questions still 
remain unanswered – it is not clear whether endothelial dysfunction can be completely 
normalized, whether normalization of endothelial function is related to adequacy of 
antihypertensive treatment, and whether antihypertensive drugs importantly differ in their 
ability to improve endothelial dysfunction. In this regard, ACE inhibitors seem to be the 
most appropriate class of antihypertonic agents (Virdis & Ghiadoni, 2011). Endothelial 
dysfunction could also be improved by substances with protective function on endothelium 
such as L-arginine, low-cholesterol diet, exercise and antioxidants (vitamin C) (Kabat & 
Dhein, 2006). Significance of the measures taken in the improvement of endothelial function 
is of greater importance when we consider the results from studies showing that 
cardiovascular morbidity and mortality very much depends on the severity of endothelium 
dysfunction (Kitta et al., 2005). 
3.2 Morphological changes of the large arteries – atherosclerosis 
EH is an important risk factor for atherosclerosis. As the cellular and molecular pathogenetic 
mechanisms of atherosclerosis and the effects of hypertension are being more clearly 
defined, it becomes apparent that the two processes have certain common mechanisms. The 
endothelium is a likely source of interaction between both diseases. NO acts as a vasodilator 
and inhibits platelet adherence and aggregation, smooth muscle proliferation, and 
endothelial cell-leukocyte interaction. Furthermore, a decrease in NO activity may 
contribute importantly to the initiation and progression of atherosclerotic lesions. It is 
proposed that several interrelated cellular and molecular processes such as inflammation 
are a likely consequence of mechanical and chemical damage of the endothelium by 
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different risk factors, including hypertension (Badimon & Fuster, 1993; Bondjers et al., 1991; 
Fuster et al., 1992; Landmesser & Drexler, 2007). However, recent observations favour the 
hypothesis that endothelial dysfunction in EH could be a primary defect and as such 
directly inherited (Bondjers et al., 1991; Vane et al., 1990; Žižek et al., 2001a; Žižek & Poredoš 
2001b). Irrespective of the sequence of events, endothelial dysfunction promotes 
atherogenesis through different mechanisms: expression of adhesions molecules, increased 
adherence of monocytes and platelets, enhanced permeability of the endothelium layer to 
monocytes/macrophages and lipoproteins, which then accumulate in the vessel wall. As the 
atherosclerotic process progresses to plaque formation growth factors secreted by 
macrophages stimulate smooth muscle cells migration, proliferation and interstitial collagen 
synthesis. In the late stages of disease, the event that initiates the development of the 
majority of myocardial infarctions is the rupture of the fibrous cap of the plaque inducing 
thrombus formation. (Fuster et al., 1998; Ross, 1993).  
It must be emphasized that risk factors for atherosclerosis tend to cluster, and therefore EH 
is rarely the only risk factor found in an individual patient. Hypertension is often 
accompanied by the metabolic syndrome, which encompasses a cluster of risk factors: 
obesity, dyslipidemia, glucose intolerance, a pro-thrombotic (high levels of fibrinogen and 
plasminogen activator inhibitor-1) and a pro-inflammatory state (high levels of tumor 
necrosis factor-, interleukin-1, -2, C-reactive protein) (Devaraj et al., 2003; DeFronzo & 
Ferrannini, 1991; Tamakoshi et al., 2003). It is proposed that these heterogeneous groups of 
clinical conditions favor atherogenesis. People with the metabolic syndrome are at increased 
risk of coronary heart disease and other diseases related to plaque buildups in the arterial 
wall (e.g., stroke and peripheral vascular disease) (Olijhoek et al., 2004). 
Assessment of the earliest morphological abnormalities in the arterial wall by B-mode 
ultrasound has been reported two decades ago. Diffuse thickening of the inner layer of 
arterial wall could be measured and followed by this non-invasive method (Pignoli et al., 
2006). However, the method does not differentiate intima from media. Therefore both 
entities are measured together as the intima-media thickness (IMT) (Salonen et al., 1993). 
IMT of large peripheral arteries, especially carotid arteries, can be assessed by B-mode 
ultrasound in a relatively simple way. Due to tight associations between atherosclerotic 
changes in the carotid arteries and in other parts of the circulation, especially coronary 
arteries, carotid arteries could be regarded as a gateway enabling us to estimate the 
progression of arterial disease (Poredoš, 2004). Carotid arterial IMT is used in studies as a 
surrogate endpoint to measure progression of atherosclerosis. Several studies have shown a 
significant relationship between IMT and cardiovascular risk factors, such as age, male 
gender, cholesterol levels, BP, diabetes mellitus and smoking habits (Poredoš et al., 1999; 
Salonen et al., 1993; Žižek & Poredoš, 2002). Thicker IMT could be detected in healthy 
normotensive offspring of parents with EH, thus implying that morphological changes 
could be directly inherited (Žižek & Poredoš, 2002).  
The relation between IMT and EH was confirmed in interventional studies. One of the 
largest studies, ELSA (European Lacidipine Study on Atherosclerosis) assessed IMT in EH 
patients. It showed that slowing of progression of the thickening could be achieved only by 
some drugs irrespective of the comparable lowering of the BP (Tang et al., 2000). This 
finding is important because in recent years we got strong evidence that IMT is an 
independent risk factor for cardiovascular events and is a better predictor of events than all 
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other known single conventional risk factors. In a Finnish study, ultrasonographic 
assessment of 1,257 men was compared with diagnostic information obtained from a 
prospective registry for acute myocardial infarction; it concluded that for each 0.1 mm of the 
common carotid IMT, the risk for a myocardial infarction increased by 11% (Salonen et al., 
1993). 
Recently, ample interest has been devoted to the relationship between arterial stiffness and 
cardiovascular disease. Pulse pressure and pulse wave velocity, surrogate measurements of 
arterial stiffness, indicate that arterial stiffness increases both with age and in certain disease 
states that are themselves associated with increased cardiovascular risk, including 
hypertension, diabetes mellitus and hypercholesterolemia (Glasser et al., 1997). Arterial 
stiffness may be measured using a variety of different techniques, mainly ultrasound based. 
Applanation tonometry pulse wave velocity is the most commonly used parameter in 
detecting central arterial stiffness (Nichols, 2005). Arterial stiffening has been particularly 
implicated in the development of isolated systolic hypertension and heart diseases leading 
to increased cardiovascular morbidity and mortality (Laurent et al., 2001). 
3.3 Hypertensive nephropathy 
EH is the main cause of the chronic kidney disease; however, morphologic evidence on the 
subject remains poorly understood (Fournier et al., 1994). A perennial problem in 
understanding the interaction between kidney and hypertension is the poor correlation 
between hypertension, and vascular and glomerular lesion. This is in part due to these 
lesions being present to a greater or lesser degree in the normotensive, aging kidney, with 
racial differences in severity further confounding the problem. Recent experimental and 
clinical data suggest that functional impairment and vasoconstriction in afferent arterioles 
(renal autoregulation) precede morphologic lesions. Progression of the endothelial 
dysfunction and consequent alterations in autoregulation of renal blood flow at higher 
pressures enable to dilate afferent arterioles transferring elevated BP to the glomeruli. The 
latter mechanism finally leads to glomerulosclerosis. Histological changes in the arterioles 
(stiffness) are present as intimal thickening, afferent arteriolar hyalinosis and smooth muscle 
atrophy. Loss of renal autoregulation with glomerular hypertrophy, hyperfiltration, and 
focal segmental glomerulosclerosis is now recognized to contribute significantly to 
nephrosclerosis, particularly in the black population. However, ischemic glomerulosclerosis 
may ultimately be the most important lesion, with consequent hypoxia in the parenchyma 
leading to tubular atrophy and interstitial fibrosis. Pathomorphological changes contribute 
variably to renal failure according to the level of hypertension (Freedman et al., 1995; Hill, 
2008) 
Recent studies provided convincing evidence that overactivation of RAAS, or part of it, may 
play a key role in functional and morphological abnormalities found in hypertensive 
nephrosclerosis (Volpe et al., 2002). In line with this statement, interventional studies 
showed that ACE inhibitors, AT1 receptor blockers (ARBs) and direct renin inhibitors such 
aliskiren may slow down or stop progression of chronic kidney disease (Momback & Toto, 
2009; Riccioni, 2011). 
Hypertensive nephropathy often results in chronic renal failure, which mostly occurs 
unnoticed and without clinical symptoms. It has been shown that even a minimal reduction 
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of renal function could be regarded as an independent risk factor for cardiovascular 
mortality and morbidity (Ruilope & Bakris, 2011; Segura et al., 2004). Hypertensive 
nephropathy can be detected by means of early signs such as the occurrence of mild 
albuminuria and reduced glomerular filtration rate, both of which are easily measured 
parameters. Albuminuria can be traced to functional and morphological transformational 
processes in the glomeruli that are associated with increased permeability (Hill, 2008). A 
recent study demonstrated that increasing albuminuria is associated with an exponential 
increase in the risk of developing chronic renal failure and cardiovascular complications 
(Levey et al., 2009). 
Rigorous, mostly multidrug antihypertensive therapy can prevent the progression of 
chronic renal failure and albuminuria/proteinuria and thereby improve both, renal and 
cardiovascular prognosis (Ruilope & Bakris, 2011). Hence, treatment with ARB (losartan) as 
shown in the LIFE study reduction of albuminuria in hypertensive patients with left 
ventricular (LV) hypertrophy is associated with fewer cardiovascular complications (Ibsen 
et al., 2005). 
3.4 Hypertensive heart disease 
The heart in EH is affected very often and sometimes very early. LV hypertrophy, diastolic 
dysfunction and reduced coronary vasodilation reserve are direct manifestations of 
cardiovascular target organ damage in patients with arterial hypertension and signify 
hypertensive heart disease. Coronary artery disease, afflicted by atherosclerotic processes is 
another indirect consequence of hypertension. All these pathophysiological conditions are 
interrelated and may end in myocardial infarction, heart failure and arrhythmia (Schmieder, 
2010).  
3.4.1 Abnormalities in left ventricular diastolic function  
The term diastolic dysfunction is used to describe abnormalities of ventricular filling, 
including decreased diastolic distensibility and impaired relaxation. LV is not able to accept 
adequate blood volume without compensatory increase of the filling pressure (Zile & 
Brutsaert, 2002). Diastolic dysfunction is thought to represent an important 
pathophysiological intermediate between hypertension and heart failure, especially in heart 
failure with normal ejection fraction (Sanderson, 2007). Up to 50% of patients with history of 
hypertension have evidence of diastolic dysfunction, which represents an attractive target 
for heart failure prevention (Fischer et al., 2003). However, to date no specific treatments 
have been definitively shown to improve diastolic function and clinical outcome (Solomon 
et al., 2007). 
Diastolic dysfunction is considered the earliest functional change in evolving hypertension 
and could be measured before morphological abnormalities (hypertrophy) ensue. We 
reported that LV filling abnormalities were detected in normotensive offspring of 
hypertensive families suggesting that diastolic dysfunction is affected by factors other than 
BP (Žižek et al., 2008). Diastolic filling abnormalities in hypertensive heart disease result 
from a delayed LV relaxation and in the later stages from a reduced LV compliance due to 
increased myocardial fibrosis (Zile & Brutsaert, 2002). Systemic/local RAAS or parts of it 
and ET-1 have been reported as factors influencing fibrosis (Bӧhm et al., 2011; Hart et al., 
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2001). The mechanisms involved in delayed relaxation are not completely understood, but 
altered myocardial metabolism of energy-rich phosphates has been proposed (Lamb et al., 
1999). In hypertensive patients decreased concentration of ATP and increased concentration 
of other phosphates leading to disturbances in Ca++ homeostasis have been reported (Lamb 
et al., 1999). Decreased levels of Ca++ in sarcoplasmic reticulum not only impair LV systolic 
function but also delay relaxation, which may ultimately end in abnormalities in LV filling 
properties and heart failure (Piacentino et al., 2003).  
Recent experimental studies have firmly established that NO released from coronary 
endothelial cells and from myocytes exerts several specific effects on myocardial function, 
analogous to endothelial regulation of vascular wall function (Paulus & Shah, 1999). In 
particular, these include selective enhancements of myocardial relaxation (Cotton et al., 
2001) and reduction in myocardial oxygen consumption (Xie et al., 1996). Several other 
paracrine and autocrine effects of NO on myocardial function have been described, e.g. 
modulating inotropic state (Cotton et al., 2001), modulating sarcolemmal Ca++ homeostasis 
(Piacentino et al., 2003) and inhibiting growth-promoting effects of norepinephrine in 
myocites and fibroblasts (Calderone et al., 1998; Ruetten et al., 2005). 
Echocardiography is now the most commonly used noninvasive tool for assessment of 
cardiac function. Detailed information can be obtained by standard pulsed Doppler 
echocardiography and from recent developed tissue Doppler-, strain rate- and speckle 
tracking imaging (Wang & Nagueh, 2009).  
3.4.2 Left ventricular hypertrophy 
An increase in peripheral vascular resistance is the hallmark of established hypertension. 
Following sustained hypertension the heart develops concentric hypertrophy that is 
characterized by thickening of LV walls. Hypertrophic process is initially adaptive and 
enables the heart to neutralize wall stress associated with increased impedance to 
ventricular emptying (afterload) (Grossman, 1980). Moreover, this thickening process is 
accompanied by a series of maladaptive changes that occur in the extracellular matrix as 
well as in cardiac myocytes. The presence of LV hypertrophy is clinically important because 
it is associated with an increased incidence of myocardial infarction, heart failure, 
ventricular arrhythmias and sudden cardiac death (Muiesan et al., 1996). 
Pathogenetic mechanisms leading to LV hypertrophy and dysfunction in EH are not 
completely understood. It seems that they are results of various interrelated hemodynamic 
and non-hemodynamic factors. Sometimes hypertrophy can be detected in the 
prehypertensive period of evolving hypertension implying that a genetic background could 
also play a role (Žižek & Poredoš, 2008). One fundamental component of cardiomyocyte 
response to pressure overload of the LV is a slowing of maximum shortening velocity 
(Vmax). Diminution of Vmax is beneficial at the cardiomyocyte level, allowing the cardiac fiber 
to contract at a normal energy cost. However, at the LV level the diminution of Vmax is the 
first step that will finally lead to heart failure (Swynghedauw et al., 2010). Another 
component of the response of the myocyte to pressure overload includes increased cell size, 
caused by multiplication of contractile units and, according to the law of Laplace this will 
normalize wall stress and preserve LV chamber function (Frohlich et al., 2011). An 
additional component of the cardiomyocyte response involves a shift in substrate oxidation 
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from fatty acids (FAs) toward carbohydrates (Akki & Seymour, 2008). Although in terms of 
oxygen cost, the oxidation of glucose is more efficient than that of FAs, in absolute terms the 
oxidation of one molecule FAs yields far more ATP than glucose. Accordingly, the 
hypertrophied heart is an energy-compromised organ with a diminished ATP production. 
On the other hand, a sustained decline in FAs oxidation may cause inappropriate 
accumulation of lipids in the hypertrophied cardiomyocyte resulting in contractile 
dysfunction (Neubauer, 2007). 
The re-expression of the cardiomyocyte fetal gene program is essential for the 
abovementioned pathophysiological responses to sustained hypertension (Barry et al., 2008). 
Activation of the fetal gene program allows coordinated synthesis of proteins necessary to 
bring about increased cardiomyocyte size and adjustment to the altered energy demands of 
these larger cells. Recent studies have revealed that in conditions of pressure overload both 
neurohumoral factors and physical stretch stimulate protein G and phospholipase C leading 
to activation of several signaling molecules including Ca++-dependent proteins (i.e., 
Ca++/calmodulin and calcineurin), protein kinases (i.e., protein kinase C and mitogen-
activated protein kinases ERK, JNK and p38), and intracrine growth factors (i.e., angiotensin 
II) that result in altered gene expression associated with pathological cardiomyocyte 
hypertrophy (Baker et al., 2004; Dorn & Force, 2005). 
Systemic/local RAAS is an important pathogenetic mechanism in development of 
hypertensive heart disease (Agabiti-Rosei & Muiesan, 2001, Schunkert et al., 1997). 
Experimental studies on hypertensive rat hearts and cell culture media confirm cardiotropic 
effects of angiotensin-II (Brilla et al., 1994). The angiotensin II has direct influences on 
various pathophysiological abnormalities in intracellular Ca++ handling, metabolism of 
contractile proteins and myocardial remodeling (Agabiti-Rosei & Muiesan, 2001). Studies 
performed during the last two decades have provided evidence that complex changes in 
myocardial composition are responsible for the morphological remodeling of the 
myocardium in hypertensive heart disease beyond cardiomyocyte hypertrophy (Frohlich et 
al., 2011). Exaggerated deposition of collagen fibers types I and III promoting interstitial and 
perivascular fibrosis, which is a well recognized lesion in hypertrophied myocardium 
(Weber, 2000). The interstitial fibrosis increases myocardial stiffness, thus facilitating LV 
diastolic dysfunction and diastolic heart failure (Neubauer, 2007). Mounting evidence shows 
that fibrosis may be a reparative response of fibroblasts induced by pro-inflammatory and 
pro-fibrotic factors, such as aldosterone (Bӧhm et al., 2011; Young, 2008). In alignment with 
the latter statement, epidemiologic studies show that aldosterone is a predictor of future EH 
and cardiovascular complications (Blacher et al., 1997; Vasan et al., 2004). 
Beyond hemodynamic and humoral factors, the genetic background may also influence 
myocardial composition in hypertensive heart disease. Up to 60% of the variance of LV mass 
may be due to genetic factors independent of BP. An increasing number of genes have been 
described, including members of the RAAS system, the type A human natriuretic peptide 
receptor gene, protein G gene affecting the Na+/H+ exchanger, as well as genes related to 
contractility and function such as the myosin-binding protein C and genes involved in the β-
adrenergic system (Deschepper et al., 2002). Among them, the most strongly associated with 
LV hypertrophy is the polymorphism of genes that encode components of the RAAS system 
(Kuznetsova et al., 2004). These non-hemodynamic factors may be involved in the 
development of inappropriate LV mass, which is defined as the growth of the LV exceeding 
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the individual needs to compensate hemodynamic load imposed by increased BP (Agabiti-
Rosei & Muiesan, 2001). Moreover, increased LV mass may be associated with cardiac 
dysfunction and adverse cardiovascular prognosis (Muiesan et al., 1996). 
Echocardiography is the gold standard test for LV hypertrophy. It can precisely estimate a 
patient's left ventricular mass and assess for other morphological cardiac abnormalities. 
Electrocardiography is more commonly used in everyday practice; it is more cost-effective 
and has high specificity, but lower sensitivity (Schmieder, 2010). 
In recent years, many papers dealing with antihypertensive therapy have been published. 
Treatment of hypertension accompanied with LV hypertrophy has shown that each and 
every class of available antihypertensive drugs could diminish LV mass but with different 
efficacy. ACE inhibitors and ARBs seem to be superior to other classes of antihypertonic 
agents (Dahlöf et al., 1992; Oren et al., 1996). Later on the investigators demonstrated that 
reduction of the LV mass is associated with reduced cardiovascular risk (Verdecchia et al., 
2003) and that observed clinical benefit with ACE inhibitors and ARBs tended to be greater 
than that expected from a decrease in BP. These potential effects “beyond BP control” are 
perhaps responsible for the protective properties of these drugs interfering with RAAS 
system-mediated myocardial remodeling (Devereux et al., 2004). However, data from the 
large ONTARGET/TRASCEND study has shown that treatment with an ARB (telmisartan) 
alone or in combination with an ACE inhibitor (ramipril) was associated with a lower 
prevalence of LV hypertrophy, but this was ultimately not translated into a prognostic 
benefit (Verdecchia et al., 2009). Whatever the causes of these unsatisfactory results, the 
unacceptably high residual risk still persisted in treated hypertensive patients in whom LV 
mass decreased with the treatment (Zanchetti, 2009).  
Increasing evidence suggests that aldosterone receptor blockade (spirinolactone, 
eplerenone) may prevent myocardial fibrosis in patients with hypertensive heart disease 
independent of its effects on BP (Bӧhm et al., 2011; Jansen et al., 2009). In patients with EH, 
addition of low-dose spirinolactone to an ACE inhibitor (enalapril/trandolapril) or ARB 
(candesartan) resulted in a greater decrease in LV mass and fibrosis than any of these drugs 
alone (Sato et al., 2002; Taniguchi et al., 2006). The failure of ACE inhibition to achieve 
regression of LV hypertrophy might in part be caused by the phenomenon of aldosterone 
escape, which means the inability of ACE inhibitor therapy to reliably suppress aldosterone 
release (Sato & Saruta, 2001). 
3.4.3 Reduced coronary reserve 
Reduced coronary vasodilation reserve is a typical complication in patients with established 
hypertension and may be presented in the absence of angiographically demonstrable 
atherosclerotic disease (Antony et al., 1993). Reduced coronary microcirculatory reserve 
could be even detected in hypertensive patients without LV hypertrophy (Brush et al., 1988). 
Authors have reported that functional and morphological abnormalities in microcirculation 
may appear very early in evolving EH. Functional (endothelial dysfunction) changes could 
be the first event, with morphological changes of vessels ensuing later on (Schiffrin, 1992). 
Functional abnormalities of the vessels are evidenced by blunted response to 
pharmacological and physiological stimuli (Drexler & Zeiher, 1991). An interrelationship 
between endothelial dysfunction and microvascular angina (syndrome X) has been 
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proposed. This clinical setting is characterized by angina-like pain and abnormal exercise 
electrocardiography changes in the presence of a normal coronary angiogram (Scheler et al., 
1994). The role of endothelial dysfunction in this setting is controversial. It has been shown 
that patients with microvascular angina have endothelial dysfunction in the resistance 
vessels, possibly as result of diminished formation of NO. However, other studies on 
coronary arteries in patients with syndrome X were unable to find signs of endothelial 
dysfunction (Bøtker & Ingerslev, 2000). 
Morphological changes in small arteries in hypertrophied LV and unbalance between 
increased LV mass and blood supply are the another pathophysiological mechanisms 
underlying a reduced coronary reserve in small arteries (Agabiti-Rosei & Muiesan, 2001). It 
has been suggested that morphological abnormalities (such as increased media/lumen ratio 
due to hypertrophy and/or hyperplasia of myocites in the vessel wall, and the rarefaction of 
blood vessels in the myocardium) represent adaptations to an increased hemodynamic load 
imposed by increased BP (Kozakova et al., 1997). 
Some controversy in the literature exists whether endothelial dysfunction in small resistance 
vessels could be influenced by drugs. In experimental animal models, improvement or even 
normalization by ACE inhibitor (captopril) and ARB (losartan) were reported (Rodrigo et 
al., 1997). In human studies, improvement was only noticed after a single application of 
captopril (Hirooka et al., 1992). Conversely, months of therapy with ACE inhibitors and 
ARBs resulted in only a slight or no effect on endothelial function in resistance arteries 
(Ghiadoni et al., 2000; Kiowski et al., 1996). 
4. Conclusions 
The results of recent studies emphasize the key role of endothelial function in the 
pathogenesis of essential hypertension. In accordance with the microcirculation theory, 
functional and morphological changes in small resistance vessels are thought to be the cause 
and consequence of hypertensive disease. This condition is predisposed by abnormal 
endothelial cell function, which is characterized by decreased production of nitric oxide and 
unbalanced production of other vasoactive substances (angiotensin II, endothelin-1, 
prostacyclin, and aldosterone) and reactive oxygen species. The target organ damage in 
conduit arteries (atherosclerosis), kidney (nephrosclerosis) and heart (diastolic dysfunction, 
left ventricular hypertrophy, reduction of coronary reserve) are the consequence of elevated 
blood pressure. There is currently no effective treatment known for hypertension. It is 
important to treat hypertension in the early stages, when preventive measures and 
antihypertensive therapy (preferably angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers) are most effective. Nowadays, non-invasive ultrasound based 
methods can detect abnormalities in different organs, which predict the unfavorable course 
of hypertensive disease resulting in a worse cardiovascular prognosis. 
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